Cost savings based on lower hypersensitivity and fewer administrations of pegaspargase were similarly found by Tong and colleagues in the context of the ALL-10 MR protocol in the Netherlands [21] and earlier studies reported a similar or favourable overall cost for pegaspargase compared with native asparaginase [22, 23]. Here, ASPG is linked to acute lymphoblastic leukemia.